The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours

British Journal of Cancer

Volumn 73, Issue 12, 1996, Pages 1480-1485

  Lartigau, E ^a   Guichard, M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy drugs; Excision assay; Growth delay assay; Human tumour cell lines; Tirapazamine

Indexed keywords

BLEOMYCIN; CISPLATIN; DACARBAZINE; ETOPOSIDE; FLUOROURACIL; TIRAPAZAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CYTOTOXICITY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LETHALITY; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RECTUM CARCINOMA; TUMOR XENOGRAFT;

EID: 0030018650     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.280     Document Type: Article

References (33)

1. BREMMER JCM, STRATFORD IJ, BOWLER, J. AND ADAMS G. (1990). Bioreductive drugs and the selective induction of tumour hypoxia. Br. J. Cancer, 61, 717-721.
2. BROWN JM. (1993). SR-4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer, 67, 1163-1170.
3. BROWN JM AND LEMMON MJ. (1991). Tumor hypoxia can be exploited to preferentially sensitize tumours to fractionated irradiation. Int. J. Radiat. Oncol. Biol. Phys., 20, 457-461.
4. COLEMAN CN. (1988). Hypoxia in tumours: a paradigm for the approach to biochemical and physiological heterogeneity. J. Natl Cancer Inst., 80, 310-316.
5. COSTA AK, BAKER MA, BROWN JM AND TRUDELL JR. (1989). In vitro hepatotoxicity of SR-4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide) a hypoxic cytotoxin and potential antitumour agent. Cancer Res., 49, 925-929.
6. DOHERTY N, HANCOCK SL, KAYE S, COLEMAN CN, SHULMAN L, MARQUEZ C, MARISCAL C, RAMPLING R, SENAN S AND ROEMELING RV. (1994). Muscle cramping in phase I clinical trials of tirapazamine (SR-4233) with and without irradiation. Int. J. Radiat. Oncol. Biol. Phys., 29, 379-382.
7. DORIE MJ AND BROWN JM. (1993). Tumor-specific, schedule-dependent interaction between tirapazamine (SR-4233) and cisplatin. Cancer Res., 53, 4633-4636.
8. GATENBY RA, KESSLER HB, ROSENBLUM JS, COIA LR, MODOF SKY PJ, HARTZ WH AND BRODER GJ. (1988). Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 10, 831-838.
9. GUICHARD M. (1989). Comparison of the radiobiological properties of human tumour xenografts and rodent tumours. Int. J. Radiat. Biol., 56, 583-586.
10. GUICHARD M, GOSSE C AND MALAISE EP. (1977). Survival curve of a human melanoma in nude mice. J. Natl Cancer Inst., 58, 1665-1669.
11. GUICHARD M, DERTINGER H AND MALAISE EP. (1983). Radiosensitivity of four human tumor xenografts. Influence of hypoxia and cell-cell contact. Radiat. Res., 95, 602-609.
12. HÖCKEL M, VORNDRAN B, SCHLENGER K, BAUSSMANN E AND KNAPSTEIN PG. (1993). Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol. Oncol., 51, 141-149.
13. HOLDEN SA, TEICHER BA, ARA G, HERMAN TS AND COLEMAN CN. (1992). Enhancement of alkylating agents activity by SR-4233 on the FSaIIC murine fibrosarcoma. J. Natl. Cancer Inst., 84, 187-193.
14. KOCH CJ. (1993). Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res., 53, 3992-3997.
15. LARTIGAU E, LE RIDANT AM, LAMBIN P, WEEGER P, MARTIN L, SIGAL R, LUSINCHI A, LUBOINSKI B, ESCHWEGE F AND GUICHARD M. (1993). Oxygenation of head and neck tumors. Cancer, 71, 2319-2325.
16. LARTIGAU E, RANDRIANARIVELO H, MARTIN L, STERN S, THOMAS CD, GUICHARD M, WEEGER P, LE RIDANT A-M, LUBOINSKI B, NGUYEN T, ORTOLI J-C, GRANGE F, AVRIL M-F, LUSINCHI A, WIBAULT P, HAIE-MEDER C, GERBAULET A AND ESCHWEGE F. (1994). Oxygen tension measurements in human tumors: the Institut Gustave-Roussy experience. Radiat. Oncol. Invest., 1, 285-291.
17. LARTIGAU E AND GUICHARD M. (1995). Does tirapazamine (SR-4233) have any effect on the surviving fraction of 3 human cell lines at clinically relevant partial oxygen pressure? Int. J. Radiat. Biol., 21, 211-216.
18. MINCHINTON AL, LEMMON MJ, TRACY M, POLLART DJ, MARTINEZ AP AND BROWN JM. (1992). Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumour agents: pharmacology and activity in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys., 22, 701-705.
19. OVERGAARD J. (1991). Importance of tumour hypoxia in radiotherapy. A meta-analysis of controlled clinical trials. Radiother. Oncol., 24, S64.
20. ROCKWELL S. (1992). Use of hypoxia-directed drugs in the therapy of solid tumors. Semin. Oncol., 19, 29-40.
21. ROCKWELL S AND MOULDER JE. (1990). Hypoxic fractions of human tumors xenografted into mice: a review. Int. J. Radiat. Oncol. Biol. Phys., 19, 197-202.
22. SAKATA K, TAK KWOK T, MURPHY BJ, LADEROUTE KR, GORDON GR AND SUTHERLAND RM. (1991). Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br. J. Cancer, 64, 809-814.
23. SCHILSKY RL. (1992). Biochemical pharmacology of chemotherapeutic drugs used as radiations enhancers. Semin. Oncol., 19, 2-7.
24. SPIEGEL JF, SPEAR MA AND BROWN JM. (1993). Toxicology of daily administration to mice of the radiation potentiator SR 4233. Radiother. Oncol., 26, 79-81.
25. STEEL GG AND PECKHAM MJ. (1992). The therapeutic response of a variety of human tumour xenografts. In Human Tumour Xenografts in Anticancer Drug Development, Winograd B, Peckham MJ and Pinedo HM (eds) pp. 4-9, Springer: London.
26. TEICHER BA, LAZO JS AND SARTORELLI AC. (1981). Classification of antineoplastic agents by their selective toxicities towards oxygenated and hypoxic tumour cells. Cancer Res., 41, 73-81.
27. UCKCCCR. (1988). Guidelines for the Welfare of Animals in Experimental Neoplasia. Br. J. Cancer, 58, 109-113.
28. VAUPEL PW. (1990). Oxygenation of human tumors. Stralenther. Onkol., 166, 377-386.
29. WEISSBERG JB, SON YH, PAPAC RJ, SASAKI C, FISCHER DB AND LAWRENCE R. (1989). Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 17, 3-9.
30. WORKMAN P AND STRATFORD IJ. (1993). The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Met. Rev., 12, 73-82.
31. ZEMAN EM, BROWN JM, LEMMON MJ, HIRST VK AND LEE WW. (1986). SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 12, 1239-1242.
32. ZEMAN EM, HIRST VK, LEMMON MJ AND BROWN JM (1988). Enhancement of radiation-induced tumour cell killing by the hypoxic cell toxin SR-4233. Radiother. Oncol., 12, 209-218.
33. ZEMAN EM, LEMMON MJ AND BROWN JM (1990). Aerobic radiosensitization by SR-4233 in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys., 18, 125-132.